AMICUS THERAPEUTICS, INC.

Amicus Therapeutics is a biotechnology company focused on developing therapies for rare genetic and orphan diseases. The company's commercial portfolio centers on Galafold, an oral monotherapy approved for adults with Fabry disease carrying amenable galactosidase alpha gene variants, developed and commercialized through a collaboration with GlaxoSmithKline. Additionally, Amicus markets Pombiliti + Opfolda, a two-component treatment program for late-onset Pompe disease. The company's pipeline includes DMX-200, a chemokine receptor 2 inhibitor currently in Phase 3 development for focal segmental glomerulosclerosis, being advanced through a partnership with Dimerix Limited.

The company operates primarily in the United States and internationally, with headquarters in Princeton, New Jersey. Amicus employs approximately 511 full-time staff members and maintains a market capitalization of $4.5 billion. Revenue generation derives from product sales of approved therapies and potential future commercialization of pipeline candidates. The business model relies on both internal development capabilities and strategic partnerships to expand its rare disease portfolio and geographic market access.